DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (NCT06075953)
DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study
🩺 Plain-English Summary (8th-Grade Level)
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Who can join: Review the eligibility criteria below.
Location: Berkeley Outpatient Center — Berkeley, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- Berkeley Outpatient Center — Berkeley, California
- City of Hope -Duarte Cancer Center — Duarte, California
- City of Hope - Lennar Foundation Cancer Center — Irvine, California
- UCLA — Los Angeles, California
- UCSF — San Francisco, California
- City of Hope — South Pasadena, California
- John Muir Health — Walnut Creek, California
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- Maple Grove Cancer Center — Maple Grove, Minnesota
- Hennepin Healthcare -Minneapolis — Minneapolis, Minnesota
- University of Minnesota — Minneapolis, Minnesota
- Health Partners - Frauenshuh Cancer Center — Saint Louis Park, Minnesota
- Health Partners - Regions Hospital — Saint Paul, Minnesota
- Englewood Hospital and Medical Center — Englewood, New Jersey
- Mount Sinai Union Square — New York, New York
- Mount Sinai Chelsea — New York, New York
- Mount Sinai West — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Duke Cancer Institute — Durham, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
- Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
- Paoli Hospital — Paoli, Pennsylvania
- Lankenau Medical Center — Wynnewood, Pennsylvania
📞 Contact the Study Coordinator
Phone: (888) 343-9922
Email: k.nelson@qlhc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ductal Carcinoma in Situ
- CAN1012 in Pre-Malignant DCIS and LCIS — Portland, Oregon
- Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions — Gainesville, Florida
- Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ — Glendale, California
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ — Pittsburgh, Pennsylvania
- Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) — Stuart, Florida
Explore by condition: All Ductal Carcinoma in Situ clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.